Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR) by Doehner, H, Vyas, P, Seymour, JF, Santini, V, Stone, RM, Minden, MD, Al-Ali, HK, Del Castillo, TB, Morrill, J, Songer, S, Weaver, J, Skikne, BS, Beach, CL, Dombret, H

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care by Döhner, H, Dolnik, A, Tang, L, Seymour, JF, Minden, MD, Stone, RM, Del Castillo, TB, Al-Ali, HK, Santini, V, Vyas, P, Beach, CL, Macbeth, KJ, Skikne, BS, Songer, S, Tu, N, Bullinger, L, Dombret, H